| NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 | NOT_YET_RECRUITING | PHASE2 | 2025-09 | 2026-01 | 2025-12 |
| NCT06757738 | A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers | RECRUITING | PHASE1 | 2024-08-13 | 2025-01-31 | 2025-01-13 |
| NCT06402136 | Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers | RECRUITING | PHASE1 | 2024-04-15 | 2024-12 | 2024-08-09 |
| NCT05705505 | Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies | RECRUITING | PHASE1, PHASE2 | 2023-03-29 | 2026-02 | 2026-01 |
| NCT04739293 | Study of ON 123300 in Patients With Advanced Cancer | RECRUITING | PHASE1 | 2021-05-13 | 2024-10 | 2024-10 |
| NCT02562443 | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA | TERMINATED | PHASE3 | 2015-12-02 | 2021-07-26 | 2020-07-26 |
| NCT02168725 | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors | TERMINATED | PHASE1 | 2014-06 | 2015-12 | 2015-12 |
| NCT02075034 | Three Dosing Schedules of Oral Rigosertib in MDS Patients | WITHDRAWN | PHASE1 | 2014-05 | 2019-11 | 2019-08 |
| NCT02030639 | Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers | COMPLETED | PHASE1 | 2014-01 | 2015-08 | 2014-12 |
| NCT02107235 | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | COMPLETED | PHASE1 | 2014-01 | 2015-01 | 2014-10 |
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | COMPLETED | PHASE1, PHASE2 | 2013-08 | 2021-02-16 | 2020-12-08 |
| NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | COMPLETED | PHASE3 | 2013-08 | 2017-06-29 | 2017-06-29 |
| NCT01904682 | Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs | COMPLETED | PHASE2 | 2013-07 | 2021-05 | 2020-12 |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | COMPLETED | PHASE2 | 2013-03 | 2016-04 | 2015-03 |
| NCT01584531 | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome | COMPLETED | PHASE2 | 2012-05 | 2015-11 | 2015-05 |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer | COMPLETED | PHASE3 | 2011-05 | 2015-12 | 2015-06 |
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | COMPLETED | PHASE3 | 2010-11 | 2018-10-03 | 2018-10-03 |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | COMPLETED | PHASE1, PHASE2 | 2010-07 | 2014-06 | 2013-12 |
| NCT01168011 | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors | COMPLETED | PHASE1 | 2010-07 | 2015-12 | 2015-12 |
| NCT01165905 | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | COMPLETED | PHASE1 | 2010-01 | 2011-07 | 2011-07 |
| NCT01048619 | Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome | COMPLETED | PHASE1 | 2009-12 | 2015-12 | 2014-11 |
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | TERMINATED | PHASE1 | 2009-11 | 2015-12 | 2014-12 |
| NCT00906334 | Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | COMPLETED | PHASE2 | 2009-05 | 2013-11 | 2013-11 |
| NCT00856791 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | COMPLETED | PHASE2 | 2009-03 | 2011-07 | 2011-07 |
| NCT00867061 | Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) | WITHDRAWN | PHASE1, PHASE2 | 2009-03 | 2010-09 | 2010-06 |
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | COMPLETED | PHASE1, PHASE2 | 2009-01 | 2014-02 | 2013-09 |
| NCT01125891 | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors | COMPLETED | PHASE1 | 2009-01 | 2011-09 | 2011-09 |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | COMPLETED | PHASE1 | 2008-10 | 2015-12 | 2014-11 |
| NCT00861783 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | COMPLETED | PHASE1 | 2008-06 | 2011-07 | 2011-07 |
| NCT00861328 | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | COMPLETED | PHASE1 | 2008-02 | 2011-07 | 2011-07 |
| NCT01538537 | Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer | COMPLETED | PHASE1 | 2006-08 | 2012-01 | 2010-10 |
| NCT01538563 | Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | COMPLETED | PHASE1 | 2006-06 | 2011-11 | 2010-07 |